Modeling Combinations of Pre-erythrocytic *Plasmodium falciparum* Malaria Vaccines

Andrew S. Walker,* José Lourenço, Adrian V. S. Hill, and Sunetra Gupta

Department of Zoology, University of Oxford, Oxford, United Kingdom; The Jenner Institute, University of Oxford, Oxford, United Kingdom

**Abstract.** Despite substantial progress in the control of *Plasmodium falciparum* infection due to the widespread deployment of insecticide-treated bed nets and artemisinin combination therapies, malaria remains a prolific killer, with over half a million deaths estimated to have occurred in 2013 alone. Recent evidence of the development of resistance to treatments in both parasites and their mosquito vectors has underscored the need for a vaccine. Here, we use a mathematical model of the within-host dynamics of *P. falciparum* infection, fit to data from controlled human malaria infection clinical trials, to predict the efficacy of co-administering the two most promising subunit vaccines, RTS,S/AS01 and ChAd63-MVA ME-TRAP. We conclude that currently available technologies could be combined to induce very high levels of sterile efficacy, even in immune-naive individuals.

**INTRODUCTION**

It is estimated that, since 2000, global malaria-associated mortality has declined by 47%, largely due to increased distribution of insecticide-treated bed nets and artemisinin-based combination therapies. However, it is widely accepted that vaccine research must continue as the international community pushes for elimination, especially in light of recently emerged artemisinin resistance. The malaria parasite has a complex lifecycle, each stage of which is the target of current vaccine research, from the initial sporozoite inoculum and subsequent liver stages to erythrocytic infection; vaccines are also being developed against the sexual stages with the aim of blocking transmission.

Pre-erythrocytic (PE) parasite stages have been targeted using either whole parasite approaches or recombinant vaccines. Among the latter, the RTS,S subunit vaccine has shown moderate, short-term efficacy, with a large-scale phase III clinical trial completed in 2014. Protection is conferred mainly by anti-circumsporozoite protein (CSP) antibodies, although a contribution from CSP-specific CD4+ T cells that help antibody production cannot be ruled out. An efficacy of around 50% (95% confidence interval [CI]: 32.9–67.1%) was shown in a phase IIa controlled human malaria infection (CHMI) trial when combined with AS01B, a liposome-based adjuvant system. Another PE subunit vaccine ME-TRAP, which induces CD8+ T-cell responses against infected hepatocytes, has been shown to provide 21% sterile protective efficacy in a phase IIa CHMI trial when administered by a prime-boost regimen (ChAd-MVA). Both of these vaccines produce a substantial delay in the time to blood-stage infection among those subjects who do not show sterile protection, and levels of reduction in parasite numbers to achieve such a delay have been estimated to be in excess of 95% for both RTS,S and ME-TRAP.

It has been proposed that combinations of vaccines acting via distinct biological mechanisms could act synergistically. The aforementioned vaccines, each with well in excess of a 90% reduction in parasite numbers and discrete methods of action, could prove a potent combination. Such an effect has previously been noted in a murine model, in which a pair of T-cell- and antibody-inducing vaccines, each with around 30–35% sterile efficacy when administered alone, elicited 90% sterile efficacy upon their combination. Here, we use a mathematical model to investigate the effects of combining anti-malarial vaccines acting at different PE stages of the life cycle. We used data from control subjects within phase IIa CHMI trials to parameterize the within-host dynamics of the PE stages of *Plasmodium falciparum* and derive measures of the effects of RTS,S and ME-TRAP on infection using data from subjects who have received these vaccines. We show that high levels of sterile protection may be obtained by two vaccines which each show far lower efficacy when administered alone.

**METHODS**

**The model.** Within-host parasite dynamics are modeled by the following system of equations describing the rates of change in numbers of infected hepatocytes (H) and merozoites (M), with parameters as described in Table 1:

\[ \frac{dH}{dt} = -\alpha S H \] (1)

\[ \frac{dM}{dt} = \gamma M \] (2)

\[ H_0 = (1 - \alpha) S_0 \] (3)

\[ M_T = r H_T \] (4)

Here, \( H_0 \) and \( M_T \) specify starting conditions for the respective populations, with \( M = 0 \) when \( t < T \), where \( T \) is incubation period within the liver. There are several stochastic events in the development of malaria infection, made apparent in CHMI trials by differences between individuals in the time taken to reach defined thresholds of parasitemia. The model captures this behavior by incorporating inter-individual variation in the sporozoite inoculum (\( S_0 \)), probability of liver invasion (\( f \)), incubation period (\( T \)), and erythrocytic growth rate (\( \gamma \)). We assume that an individual receives \( n \) bites, where the size of each sporozoite inoculum, \( S_i \) (such that the total initial inoculum \( S_0 = \sum S_i \)), is sampled from a negative binomial distribution obtained by fitting a negative binomial model to counts of parasites inoculated per-bite by anopheline mosquitoes. The proportion of sporozoites invading liver cells (\( f \)) is drawn from a Poisson distribution with shape parameter...
\( e = S_0 / \lambda \), where \( \lambda \) is a modifier of sporozoite success. Vaccine-induced anti-sporozoite immune responses reduce the probability of invasion by \((1 - \alpha_1)\), while infected hepatocytes are removed by a liver-stage vaccine at a rate \( \alpha_2 \). Intrahepatic development takes approximately 7 days, and at the end of this period (\( T \)), the merozoite population size is set to \( rH_T \), where \( r \) is the number of merozoites released per hepatocyte. Erythrocytic growth occurs at a rate \( \gamma \), sampled from a Gaussian distribution with a given mean and standard deviation (SD; \( \gamma_{\text{mean}} \) and \( \gamma_{\text{std}} \), respectively).

The model was implemented in MATLAB R2013b (The MathWorks, Inc., Natick, MA), and the ODE system solved using a non-stiff Runge-Kutta solver, ode45.

**Model fitting to trial data.** The two studies used to parameterize the model\(^{10,11}\) utilized similar challenge protocols, and there were no significant differences in time to patentcy \( \tau_{\text{pat}} = 1.5409(34, P = 0.1326) \) between the two trials, nor was there a difference between either study and an additional study investigating time to patentcy following *Anopheles* bites.\(^{20}\) Similarly, there was no significant difference between the times to quantitative real-time polymerase chain reaction (qPCR) detection in the Ewer and Lyke studies \( \tau_{\text{qPCR}} = 1.320(22,755, P = 0.2002) \); qPCR data was not available for the RTS,S CHMI study.\(^{10}\)

The combination of parameters that provides the best fit between the ODE model and the CHMI trial data was determined using a stepwise Markov chain Monte Carlo (MCMC) methodology,\(^{21}\) detailed in Supplemental Methods. Each run of the model outputs the time from sporozoite inoculum to qPCR and blood slide detection of merozoites; these values are compared with CHMI data. Threshold levels of parasitemia were computed on the basis that 1) qPCR detection methods can reliably detect 20 parasites/mL of blood\(^{22}\) and, given \(~4.7\) L of blood in an adult human, this equates to 94,000 parasites in a single host and 2) blood slide methods generally detect parasitemia when there are between 20 and 50 parasites/mL\(^{23}\), an estimated mean of 35 was therefore used, equating to \( 1.645 \times 10^9 \) parasites across the human host.

First, a baseline model was parameterized (Supplemental Methods) using CHMI data from non-vaccinated individuals. The effects of administering two vaccines in combination were assessed by running the model 500 times under different parameters describing the proportional reduction in successful sporozoite infection and maturation of infected hepatocytes. These particular parameters for RTS,S and ME-TRAP were obtained by fitting the baseline model to CHMI data on vaccinated individuals.

The model was subjected to a sensitivity analysis by fixing (baseline model and vaccine) parameters at the values found by the MCMC procedure (Supplemental Table 2), and then varying each parameter independently about a Gaussian distribution with arbitrary SD. For each parameter value, the least squares distance of the model output to the trial data was calculated.

**RESULTS**

**Baseline within-host dynamics.** We obtained a mean time to patentcy by blood slide analysis of 11.046 days (SD = 1.205) as compared with 11.037 (SD = 1.512, \( N = 53 \)) among the controls in the CHMI trials used in this study (Figures 1A and 2A). The mean time to the qPCR detection threshold of parasitemia in the model was 7.219 days (SD = 0.592), compared with 7.759 days (SD = 1.115, \( N = 29 \)) in the CHMI trials (Figures 1A and 2B and Supplemental Table 1).

For completeness, we performed an additional sensitivity analysis (Supplemental Figure 1A–D) by resampling each parameter independently from a normal distribution with a mean of the value found by fitting. We found the goodness of fit of the model to be dependent on all parameters and, as expected, to maximize around the values found by the MCMC.

**Within-host dynamics in single vaccine recipients.** We obtained a sterile protective efficacy of 53.35% (SD = 5.20%) for RTS,S/AS01 compared with 50% (95% CI = 32.9–67.1%) reported by Kester and others\(^{10}\) (Figure 1B). In those individuals who were not protected, the mean time to patentcy by blood slide analysis in the model was 11.898 days (SD = 1.222), compared with the CHMI result of 13.567 days (95% CI = 9.78–17.37; Supplemental Figure 2A and Supplemental Table 1). Time to qPCR detection in the model was 7.896 days (SD = 0.603); this cannot be compared with

---

**TABLE 1**

| Parameter | Explanation | Value |
|-----------|-------------|-------|
| \( \alpha_1 \) | Vaccine-induced modifier of sporozoite invasion probability: \( \alpha_{1,\text{min}} = 0, \alpha_{1,\text{max}} = 1 \) | MCMC fitted |
| \( \alpha_2 \) | Vaccine-induced rate of removal of infected hepatocytes: \( \alpha_{2,\text{min}} = 0, \alpha_{2,\text{max}} = 1 \) | MCMC fitted |
| \( \mu \) | Rate of sporozoite loss, set such that sporozoites are removed from system at a realistic rate | 20 |
| \( T \) | Liver incubation time: time from sporozoite inoculum to merozoite release | Selected from Gaussian distribution, mean = 7 days, SD = 0.5 days |
| \( r \) | Successful merozoites per hepatocyte | 10,000 |
| \( f \) | Proportion of sporozoites that successfully invade hepatocytes: if, \( f > 1 \); if, \( f = 1 \) | Stochastically selected from Poisson distribution (see Methods) |
| \( \lambda \) | Shape determinant for Poisson cumulative density function from which sporozoite success rate is stochastically sampled: \( \lambda_{\text{max}} = 10 \); \( \lambda_{\text{min}} = 1 \) | MCMC fitted |
| \( S_0 \) | Initial inoculum size, based on sum of five samples (five bites) from negative binomial distribution | – |
| \( P \) | Success parameter for sampling from negative binomial to give per bite inoculum size | MCMC fitted |
| \( R \) | Shape parameter of inoculum size negative binomial\(^{19}\) | 0.246 |
| \( \gamma_{\text{mean}} \) | Mean of EGR: \( \gamma_{\text{mean},\text{max}} = 5 \); \( \gamma_{\text{mean},\text{max}} = 0 \) | MCMC fitted |
| \( \gamma_{\text{std}} \) | SD of EGR: \( \gamma_{\text{std},\text{max}} = 1.25 \); \( \gamma_{\text{std},\text{max}} = 0 \) | MCMC fitted |
| \( \gamma \) | EGR: if \( \gamma < 0 \) then \( \gamma = 0 \) | Sampled from Gaussian of mean \( \gamma_{\text{mean}} \) and SD \( \gamma_{\text{std}} \) |

EGR = erythrocytic growth rate; MCMC = Markov chain Monte Carlo; SD = standard deviation.
trial output, as qPCR data were not available in this trial (Figure 1B and Supplemental Figure 2B). This corresponds to a proportionate reduction in successful sporozoite numbers ($\alpha_1$) of 0.901 (Supplemental Table 2).

Overall, the fit of the model to the RTS,S ($\alpha_1$) data (Figure 4), which may in part be due to only blood slide patency data available for RTS,S, whereas both blood slide and qPCR data were available for ME-TRAP.

ChAd-63-MVA ME-TRAP elicited 22.72% efficacy (SD = 4.26%) in the model as compared with 21.4% (95% CI = 3.2–46.0%) in the study by Ewer and others.\textsuperscript{11} The mean time to blood slide and qPCR detection in non-protected individuals in the model were 11.008 days (SD = 1.054) and 7.208 days (SD = 0.76), respectively, compared with 12.82 days (95% CI = 8.72–6.91) and 8.91 days (95% CI = 5.41–12.41) in the vaccine trial (Figure 1C, Supplemental Figure 2C, D, and Supplemental Table 1). This corresponds to a proportionate reduction in infected hepatocytes ($1 - \exp(-\alpha_2 \times T)$) of 0.780 (Supplemental Table 2).

Effects of combining vaccines. Sterile protective efficacies of combinations of vaccines acting at sporozoite and liver stages were evaluated by varying $\alpha_1$ and $\alpha_2$ to reflect a proportionate reduction in parasite numbers ranging from 0.5 to 1 (Figure 3). We found that the parameters identified for RTS,S and ME-TRAP from the CHMI data conferred very high levels of sterile protection when the vaccines were combined (Figure 3, intersection of double lines): 97.51% (SD = 1.52%) of infections were prevented in 500 runs of the model with $\alpha$ values fixed at the values found by MCMC fitting. A small increase in percentage killed for either vaccine would effectively
of vaccine-induced immune responses to elicit sterile protection, even in individuals in whom all but a few parasites are eradicated, infection is likely to occur, albeit with a slight delay. Previous studies have estimated two PE subunit vaccines currently in development, ChAd63-MVA ME-TRAP and RTS,S/AS01, to independently eradicate in excess of 90% of parasites,11,12, and yet sterile efficacies remain moderate to modest.8,10,11,24,25 We suggest that combinations of vaccines with such strong parasite-killing effects will be significantly more efficacious than the aforementioned, although highly promising, single-vaccine approaches.

Our estimates of the combined efficacy of ChAd63-MVA ME-TRAP and RTS,S/AS01 would be sufficient, at high coverage, to eliminate malaria in areas where the transmission potential ($R_0$) of malaria is moderate25 ($\sim 5$), and would extend to areas of much higher transmission by even very slightly increasing the rate of parasite killing for either vaccine. There is considerable debate concerning the measurement of $R_0$ for malaria,27,28 but methods that account for antigenic diversity and low rates of development of natural immunity28 suggest maximum values that fall well within the range of possible elimination associated with the combined efficacy of ChAd63-MVA ME-TRAP and RTS,S/AS01. The duration of efficacy remains a problem in achieving the goal of elimination: to date, 13 PE and nine erythrocytic vaccines have entered clinical trials,5 but very few have been found to demonstrate lasting protective efficacy in humans, despite high antibody titers or T-cell levels.4 Thus, although our model supports the notion that a highly efficacious PE subunit vaccine may well be within reach, control of malaria is likely to be sustained only when used in conjunction with other tools5 such as bednets29 and fungal biopesticides.30

A paradox arises when trying to fit the model to data on infection dynamics among recipients of ME-TRAP (Figure 1C) in that the recorded delay to thresholds of parasitemia require less than one liver cell’s worth of merozoites to be released. This suggests that ME-TRAP, as well as inducing total destruction of liver cells, may cause partial disruption of others, allowing them to release a partial load of merozoites. Partial release of merozoite load may also be a feature of natural infection, as noted by Bejon and others in trying to replicate infection in murine models.31 Infection dynamics among recipients of ME-TRAP (Figure 1C) indicates that there is a delay to a threshold of parasitemia, but a few parasites are eradicated, infection is likely to occur, albeit with a slight delay. Previous studies have estimated two PE subunit vaccines currently in development, ChAd63-MVA ME-TRAP and RTS,S/AS01, to independently eradicate in excess of 90% of parasites,11,12, and yet sterile efficacies remain moderate to modest.8,10,11,24,25 We suggest that combinations of vaccines with such strong parasite-killing effects will be significantly more efficacious than the aforementioned, although highly promising, single-vaccine approaches.

Our estimates of the combined efficacy of ChAd63-MVA ME-TRAP and RTS,S/AS01 would be sufficient, at high coverage, to eliminate malaria in areas where the transmission potential ($R_0$) of malaria is moderate25 ($\sim 5$), and would extend to areas of much higher transmission by even very slightly increasing the rate of parasite killing for either vaccine. There is considerable debate concerning the measurement of $R_0$ for malaria,27,28 but methods that account for antigenic diversity and low rates of development of natural immunity28 suggest maximum values that fall well within the range of possible elimination associated with the combined efficacy of ChAd63-MVA ME-TRAP and RTS,S/AS01. The duration of efficacy remains a problem in achieving the goal of elimination: to date, 13 PE and nine erythrocytic vaccines have entered clinical trials,5 but very few have been found to demonstrate lasting protective efficacy in humans, despite high antibody titers or T-cell levels.4 Thus, although our model supports the notion that a highly efficacious PE subunit vaccine may well be within reach, control of malaria is likely to be sustained only when used in conjunction with other tools5 such as bednets29 and fungal biopesticides.30

A paradox arises when trying to fit the model to data on infection dynamics among recipients of ME-TRAP (Figure 1C) in that the recorded delay to thresholds of parasitemia require less than one liver cell’s worth of merozoites to be released. This suggests that ME-TRAP, as well as inducing total destruction of liver cells, may cause partial disruption of others, allowing them to release a partial load of merozoites. Partial release of merozoite load may also be a feature of natural infection, as noted by Bejon and others in trying to replicate infection dynamics among CHMI controls.12 There are several potential mechanistic explanations for this phenomenon. It appears that hepatocytes do not “burst” per se, rather, vesicles called merosomes, each containing 100–200 merozoites, bud from the infected cell,31 and it has been shown that merozoite exit from the liver can be affected by inflammatory immune responses restricting blood flow.32 Furthermore, the inherent stochasticity in the erythrocytic invasion process12 may be partially responsible for the range in times to qPCR detection and patency by blood slide analysis seen in CHMI studies.33 Finally, it is likely that there is heterogeneity in the spread of parasites across the body. For example, release of the merozoite cargo has been shown in a murine model to occur mostly in the lungs34: parasites are released into deep vasculature, whereas blood for qPCR detection and thick smear analysis is taken from more peripheral sources.

We have assumed that there is no interaction between the T-cell- and antibody-mediated responses to ChAd63-MVA ME-TRAP and RTS,S/AS01. An important consideration in future work will be, when combining vaccines, whether interactivity exists between the mechanisms by which they act. Furthermore, certain candidate vaccines may affect more than one stage in the life cycle: for example, the blood-stage candidate apical membrane antigen 1 (AMA-1), also plays a role in hepatocyte invasion35 and has demonstrated promising efficacy correlated with cell-mediated immunity when combined with a PE antigen.36 Our model provides a platform to investigate the non-additive effects of the various combinations of vaccines that are likely to be tested in the near future in our ongoing battle against malaria.

Received December 1, 2014. Accepted for publication August 6, 2015. Published online October 26, 2015.
Note: Supplemental methods, table, and figures appear at www.ajtmh.org.

Acknowledgments: We would like to acknowledge the use of the University of Oxford Advanced Research Computing (ARC) facility in carrying out this work. Andrew S. Walker, José Lourenço and Sunetra Gupta are funded by the European Research Council (ERC Advanced Grant—Diversity). AVSH is a Jenner Investigator and Wellcome Trust and NIHR Senior Investigator.

Authors’ addresses: Andrew S. Walker, José Lourenço, and Sunetra Gupta, Department of Zoology, University of Oxford, Oxford, United Kingdom, E-mails: andrew.walker@zoo.ox.ac.uk, jose.lourenco@zoo.ox.ac.uk, and sunetra.gupta@zoo.ox.ac.uk. Adrian V. S. Hill, The Jenner Institute, University of Oxford, Oxford, United Kingdom, E-mail: adrian.hill@ndm.ox.ac.uk.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. World Health Organization, 2014. World Malaria Report 2014. Geneva, Switzerland: WHO.

2. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hindley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez M-G, Ghani AC. 2010. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 7: e1000324.

3. Dondorp A, Nosten F, Yi P, 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.

4. Schwartz L, Brown GV, Genton B, Moorthy VS, 2012. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 11: 11.

5. WHO, 2014. Malaria Vaccine Rainbow Tables. Available at: http://www.who.int/vaccine_research/links/Rainbow/en/index.html. Accessed January 6, 2015.

6. The RTSS Clinical Trials Partnership. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863–1875.

7. The RTSS Clinical Trials Partnership. 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11: e1001685.

8. The RTSS Clinical Trials Partnership. 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31–45.

9. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC. 2013. The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PLoS One 8: e61395.

10. Kester KE, Cummings JF, Ofori-Aninyam O, Ockenhouse CF, Kryzhi U, Moris P, Schwenk R, Nielsen RA, Debeze Z, Pineles E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois M, Lievens M, Cohen J, Ballou WR, Hepper DG Jr. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337–346.

11. Ewer KJ, O’Hara GA, Dunican CJA, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead BD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AVS. 2013. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee-adenoavivirus-MVA immunization. Nat Commun 4: 2836.

12. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, Gilbert SC, Peto T, Hill AVS. 2005. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 191: 619–626.

13. Ndugu FM, Mwacharo J, Kimani D, Kai O, Moris P, Jongert E, Vekeman J, Olotu A, Bejon P, 2012. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS One 7: e52870.

14. Duffy P, Kaslow D, 1997. A novel malaria protein, PfSp28, and PfSp25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 65: 1100–1113.

15. Hill AVS. 2006. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 6: 21–32.

16. Hutchings CL, Birkett AJ, Moore AC, Hill AVS. 2007. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 75: 5819–5826.

17. Moore AC, Hutchings CL. 2007. Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Rev Vaccines 6: 111–121.

18. White MT, Smith DL. 2013. Synergism from combinations of infection-blocking malaria vaccines. Malar J 12: 280.

19. Medica DL, Sinns P. 2005. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect Immun 73: 4363–4369.

20. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, Loyevsky M, Chakravarty S, Ploew CV, Sim BKL, Edelman R, Hoffman SL. 2010. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5: e13490.

21. Lourenço J, Recker M. 2014. The 2012 Madeira Dengue Outbreak: epidemiological determinants and future epidemic potential. PLoS Negl Trop Dis 8: e3083.

22. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon P, Hunt-Cook A, Bergson G, Sanderson F, Hill AV, Gilbert SC. 2005. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg 73: 191–198.

23. Guerin P, Olliaro P, Nosten F. 2002. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2: 564–573.

24. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Fust SN, Hill AVS. 2014. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 211: 1076–1086.

25. Ogwang C, Kimani D, Edwards NJ, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, Hill AVS. 2015. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenya adults. Sci Transl Med 7: 1–11.

26. Anderson RM, May RM. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press.

27. Smith DL, McKenzie FE, Snow RW, Hay SI. 2007. Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol 5: e242.

28. Gupta S, Trenholme K, Anderson RM, Day KP. 1994. Antigenic diversity and the transmission dynamics of Plasmodium falciparum. Science 263: 961–963.

29. Arzt-Randrup Y, Dobson AP, Pascual M. 2015. Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria. Proc Natl Acad Sci USA 112: 3014–3019.

30. Lynch PA, Grimm U, Thomas MB, Read AF. 2012. Prospective malaria control using entomopathogenic fungi: comparative evaluation of impact on transmission and selection for resistance. Malar J 11: 383.
31. Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok J-M, Menard R, Heussler VT, 2006. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313: 1287–1290.
32. Viriyavejakul P, Khachonsaksumet V, Punsawad C, 2014. Liver changes in severe Plasmodium falciparum malaria: histopathology, apoptosis and nuclear factor kappa B expression. Malar J 13:106.
33. Roestenberg M, O’Hara GA, Duncan CJA, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJAM, Hermsen CC, Hill AVS, Sauerwein RW, 2012. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 7: e38434.
34. Baer K, Klotz C, Kappe SHI, Schnieder T, Frevert U, 2007. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 3: e171.
35. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH, Thomas AW, Van Gemert GJ, Sauerwein RW, Blackman MJ, Anders RF, Pluschke G, Mazier D, 2004. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 9490–9496.
36. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tammenga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banjara JG, Huang J, Newcomer R, Rein L, Litil D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Digg C, Hollingdale MR, Ockenhouse CF, Richie TL, 2013. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8: e55571.